Moderna 2022 Priorities and Capital Allocation
Moderna as of May 2022
Pipeline
Programs in development
•
Commercial
Moderna COVID-19
Vaccine/SpikevaxⓇ
Phase 3
Phase 2
COVID boosters, RSV,
CMV
Flu, Zika, PCV, VEGF-A
Respiratory vaccines
COVID variant boosters (variant-specific
and bivalents) in Phase 2/3
Older adults RSV in Phase 3; Pediatric RSV
in Phase 1
Flu in Phase 2; Phase 3 expected to start in
2022
hMPV + PIV3 in Phase 1b age de-
escalation study
Flu + COVID, Flu + COVID + RSV, RSV +
hMPV, Endemic HCoV in preclinical
Latent vaccines
•
.
CMV in Phase 3
• EBV, HIV in Phase 1
HSV, VZV in preclinical
Public health
vaccines
Zika in Phase 2
·
Nipah in preclinical
Foundations
Slide 7
•
•
.
46 development
programs
mRNA therapeutics
15 medicines in 4 therapeutic areas
5 Immuno-Oncology: PCV in Ph 2; KRAS, Triplet, IL-12 in Ph 1;
Checkpoint in preclinical
6 Rare Diseases: PA, MMA in Ph 1/2; GSD1a, PKU, CN-1, CF
in preclinical
2 Cardiovascular Diseases: VEGF-A in Phase 2; Relaxin in
preclinical
2 Autoimmune Diseases: IL-2 in Ph 1; PD-L1 in preclinical
~3,200
employees
Science 2021
TOP EMPLOYER
7th
Consecutive year
top employer by
Science
(1) As of March 31, 2022; Cash and investments denotes cash, cash equivalents and investments
11 commercial
subsidiaries across North
America, Europe and Asia
Pacific
~$19.3B
of cash and
Investments
(unaudited)1
modernaView entire presentation